login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ICECURE MEDICAL LTD (ICCM) Stock News
USA
- NASDAQ:ICCM -
IL0011224156
-
Common Stock
1.02
USD
-0.03 (-2.86%)
Last: 9/25/2025, 9:36:02 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ICCM Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: IceCure Medical
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
7 days ago - By: IceCure Medical
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
17 days ago - By: IceCure Medical
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
a month ago - By: Benzinga
Examining the Future: Icecure Medical's Earnings Outlook
4 months ago - By: Benzinga
Earnings Preview For Icecure Medical
a month ago - By: The Motley Fool
IceCure Medical Advances FDA Review
a month ago - By: The Motley Fool
IceCure (ICCM) Q2 2025 Earnings Call Transcript
a month ago - By: Zacks Investment Research
- Mentions:
CODX
IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates
a month ago - By: IceCure Medical
IceCure Reports Financial & Operational Results for the First Half of 2025
2 months ago - By: Zacks Investment Research
- Mentions:
VTRS
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates
2 months ago - By: IceCure Medical
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
2 months ago - By: IceCure Medical
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
3 months ago - By: IceCure Medical
IceCure Announces Commencement of Rights Offering
3 months ago - By: IceCure Medical
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
3 months ago - By: IceCure Medical
IceCure Announces Record Date for Rights Offering for Up to $10 Million
4 months ago - By: IceCure Medical
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
4 months ago - By: IceCure Medical
IceCure Medical Reports First Quarter 2025 Financial Results
4 months ago - By: IceCure Medical
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
5 months ago - By: Zacks Investment Research
- Mentions:
AAWH
Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Misses Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
NTRA
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: IceCure Medical
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
5 months ago - By: IceCure Medical
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
5 months ago - By: IceCure Medical
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
6 months ago - By: IceCure Medical
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
6 months ago - By: IceCure Medical
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
6 months ago - By: IceCure Medical
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
6 months ago - By: IceCure Medical
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
6 months ago - By: IceCure Medical
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
Please enable JavaScript to continue using this application.